Erratum to: Boosting SN38-based oral chemotherapy to combine reduction-bioactivated structured lipid-mimetic prodrug with ascorbic acid

Helin Wang; Qi Lu; Yifan Miao; Jiaxuan Song; Mingyang Zhang; Haotian Zhang; Zhonggui He; Zixuan Wang; Chutong Tian; Jin Sun

doi:10.1007/s12274-022-5257-7

| Sign up

PDF (1.1 MB)

Cite

EndNote(RIS) BibTeX

Collect

Submit Manuscript

Show Outline

Figures (2)

Figure 9

Erratum

Erratum to: Boosting SN38-based oral chemotherapy to combine reduction-bioactivated structured lipid-mimetic prodrug with ascorbic acid

Helin Wang^{¹^,^§}, Qi Lu^{¹^,^§}, Yifan Miao^¹, Jiaxuan Song^¹, Mingyang Zhang^¹, Zixuan Wang^¹, Haotian Zhang^², Zhonggui He^¹, Chutong Tian^¹(), Jin Sun^¹

()

1Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China

2School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China

^§ Helin Wang and Qi Lu contributed equally to this work.

Show Author Information

The online version of the original article can be found at:

https://doi.org/10.1007/s12274-022-4544-7

Keywords

oral chemotherapy structured lipid-mimetic prodrug 7-ethyl-10-hydroxycamptothecin (SN38)ascorbic acid

Nano Research

Volume 16 Issue 4,
April 2023

Pages 6010-6011

DOI: 10.1007/s12274-022-5257-7

Cite this article:

Wang H, Lu Q, Miao Y, et al. Erratum to: Boosting SN38-based oral chemotherapy to combine reduction-bioactivated structured lipid-mimetic prodrug with ascorbic acid. Nano Research, 2023, 16(4): 6010-6011. https://doi.org/10.1007/s12274-022-5257-7

Figure 9In vivo antitumor efficacy of 4T1 tumor. (a) The coadministration strategy of SN38 structured lipid prodrugs and ascorbic acid to 4T1 tumor-bearing mice. (b) In vivo antitumor activity of prodrug against 4T1 in-situ tumors. (c) Body weight change in each group. (d) The images of tumors at Day 10. G1:Saline; G2:SN38 solution, p.o., 10 mg/kg; G3:SN38 lipid formulation, p.o., 10 mg/kg; G4:SN38 solution, i.v., 5 mg/kg; G5:SN38-C-C-OcA lipid formulation, p.o., 10 mg/kg; G6:SN38-C-C-OcA lipid formulation, p.o., 10 mg/kg + ASC, i.p., 400 mg/kg; G7:SN38-S-S-OcA lipid formulation, p.o., 10 mg/kg and G8:SN38-S-S-OcA lipid formulation, p.o., 10 mg/kg + ASC, i.p., 400 mg/kg. (e) Tumor burden for each group. (n = 5). *P < 0.05 and ****P < 0.0001 versus control.

Figure 9In vivo antitumor efficacy of 4T1 tumor. (a) The coadministration strategy of SN38 structured lipid prodrugs and ascorbic acid to 4T1 tumor-bearing mice. (b) In vivo antitumor activity of prodrug against 4T1 in-situ tumors. (c) Body weight change in each group. (d) The images of tumors at Day 10. G1:Saline; G2:SN38 solution, p.o., 10 mg/kg; G3:SN38 lipid formulation, p.o., 10 mg/kg; G4:SN38 solution, i.v., 5 mg/kg; G5:SN38-C-C-OcA lipid formulation, p.o., 10 mg/kg; G6:SN38-C-C-OcA lipid formulation, p.o., 10 mg/kg + ASC, i.p., 400 mg/kg; G7:SN38-S-S-OcA lipid formulation, p.o., 10 mg/kg and G8:SN38-S-S-OcA lipid formulation, p.o., 10 mg/kg + ASC, i.p., 400 mg/kg. (e) Tumor burden for each group. ( n = 5). *P < 0.05 and ****P < 0.0001 versus control.

手机微信扫描二维码，点击右上角···按钮
分享到微信朋友圈